Synergistic and attenuated effect of HSS in combination treatment with docetaxel plus cisplatin in human non-small-cell lung SPC-A-1 tumor xenograft |
| |
| Institution: | 1. Shandong Academy of pharmaceutical Sciences, Ji’nan, Shandong 250101, China;2. Shandong Laboratory Animal Center, Shandong Academy of Medical Science, Ji’nan 250002, China;3. Cancer Hospital of Qindao Haisheng Co., Ltd., Qingdao 266031, China;1. Department of Anesthesiology, Achillopouleion General Hospital of Volos, Magnesia, Greece;2. 2nd Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece;3. Clinic of Anesthesiology and Intensive Care, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Greece;4. Respiratory Medicine Department, University of Thessaly Medical School, University Hospital of Larissa, Larissa, Greece;1. Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;2. Biostatistics, Regina Elena National Cancer Institute, Roma, Italy;3. Department of Pathology and Diagnostic, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;4. Chirurgia ‘A’, Department of Surgery and Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy;1. Mayo Clinic, Rochester, MN;2. St. Anne''s University Hospital, International Clinical Research Center (ICRC), Brno, Czech Republic;3. Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic;4. Faculty of Medicine, Masaryk University, Brno, Czech Republic;5. Center for Cardiovascular and Transplant Surgery (CKTCH), Brno, Czech Republic;6. Yale University, New Haven, CT;7. Georgetown University Medical Center, Washington, DC;8. Department of Cardiology, University Hospital Olomouc, Olomouc, Czech Republic;1. Department of Hematology and Oncology, Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria;2. Department of Pulmonary Medicine II, SMZ Otto Wagner Hospital, Vienna, Austria;3. Department of Internal Medicine III, Paracelsus Medical University Hospital, Salzburg, Austria;4. Department of Pneumology, General Hospital of Linz, Linz, Austria;5. Department of Pneumology, General Hospital Wels, Wels, Austria;6. Department of Visceral and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria |
| |
| Abstract: | Platinum based combination regimens are first-line treatment option in treatment of non-small cell lung cancer (NSCLC) but the clinical utility has been limited because of their toxicities. Many reports indicated that patients with tumors can benefit from adjuvant chemotherapy drugs. The aim of this study was to confirm adjuvant chemotherapy of HSS with docetaxel plus cisplatin (DP) against NSCLC by evaluating antitumor activity and attenuated effect. In vivo SPC-A-1 xenograft model was established to evaluate antitumor activity and toxicity of HSS along or combination with DP. Evaluation indexes include the relative tumor proliferation rate, tumor growth inhibition rate, body weight, food consumption, hematological and biochemical analysis. HSS treatment showed inhibited tumor growth and increased tumor inhibition of DP treatment at doses of 250 mg/kg and 500 mg/kg. No significant toxicity was found in HSS-treated mice, but significant toxicity was found in DP-treated mice. HSS combination with DP could reduce toxicity of DP treatment by improving body weight and food consumption, and increasing the number of WBC and PLT, decreasing the level of ALT, AST and BUN. HSS combined with DP treatment has additive effect which contributes to enhance tumor growth inhibition of DP treatment and attenuated effect which contributes to reduce toxicity of DP treatment. These findings indicate potential benefit for use of HSS adjuvant chemotherapy for NSCLC treatment. |
| |
| Keywords: | HSS Antitumor activity Additive effect Toxicity Docetaxel Cisplatin |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
